Pharmaceutical major Lupin Ltd announced on Tuesday a strategic partnership with Honeywell to incorporate its eco-friendly propellant, ‘Solstice Air’, in the development of next-generation inhalers aimed at treating asthma and chronic obstructive pulmonary disease (COPD).
According to the company, Solstice Air offers a significant environmental benefit by helping reduce emissions of high global warming potential (GWP) molecules, representing a key advancement in sustainable respiratory care.
Commenting on the collaboration, Lupin CEO Vinita Gupta said, “Our partnership with Honeywell reflects our dedication to providing high-quality medicines while contributing to a healthier and more sustainable future. By using Solstice Air in our products, we are not only improving patient outcomes but also minimizing environmental impact.”